AazeinTx is pleased to announce the addition of Dr Gail Gauvreau, Dr. Dan Chiche, Dr. Kem Payza, and Dr. Bill Brown to our advisory board. These top medical and scientific experts in therapeutic development will advise the company throughout the clinical process.
AazeinTx is excited to be announced as a winner of the “Health & Preparedness” category in the NexStream Tech Challenge 2.0. While the competition was based out of the Campbell River Area in BC, AazeinTx was the only out-of-province winner thanks to the broad potential benefit of their novel asthma treatment, which is slated to move into human trials in the near future.
AazeinTx is thrilled to announce the addition of their newest advisory board expert Dr. Bill Brown. He brings over 30 years of experience in the discovery and development of small molecule drugs, including the discovery of the NEO6860 compound where he was a key inventor.
AazeinTx is excited to announce the addition of new advisory board expert Dr.Gail Gauvreau. Gail brings years of research and scientific expertise in the study of inflammatory reactions and novel target treatments for allergic diseases.
AazeinTx is pleased to announce the addition of their newest advisory board expert Dr. Dan Chiche. He has been a key agent in the clinical development of various therapeutic compounds including infectious diseases, COPD, and asthma to name a few.
adMare BioInnovations (“adMare”) and AazeinTx Inc. (“AazeinTx”) have closed a global exclusive licensing transaction for a promising acute asthma treatment.
Dr. Richard Wilson, Chief Scientific Officer of AazeinTx talks about how the company offers new hope for acute asthma therapy.
AazeinTx is excited to announce the addition of their newest advisory board expert Dr. Kemal Payza. Payza brings 27 years of pharmaceutical experience in drug discovery processes, and has made contributions to 17 candidate drugs.
UCalgary researchers find game-changing alternative to inhalers Inhalers may no longer be the only option in treating acute asthma attacks thanks to research by a UCalgary professor and his medical company supported by the UCeed program. Research led by Dr. Richard Wilson, PhD, points to a novel oral treatment for asthma that goes beyond the traditional inhaler. The new treatment is likely to be fast-acting, targeting the nervous system rather than the airways. Wilson’s lab Read more…
AazeinTx Receives Campus Alberta Neuroscience Seed Funding